Shares of Emcure Pharmaceuticals Ltd. hit the 10% upper circuit for the second consecutive day on Thursday, May 23, closing at ₹1,284.40. The stock has rallied 20% over the past two sessions following robust Q4 FY25 earnings and a target price revision by Kotak Institutional Equities.
In its March quarter results, Emcure Pharma reported a 64.4% year-on-year (YoY) jump in consolidated net profit to ₹189 crore, compared to ₹115 crore in the same period last year. Revenue rose 19.5% YoY to ₹2,116 crore from ₹1,771.3 crore, reflecting continued momentum across core markets.
The company’s strong operating performance has been further supported by a dividend announcement. The board has recommended a final dividend of ₹3 per equity share (face value ₹10) for the financial year ended March 31, 2025.
Adding to the optimism, Kotak Institutional Equities raised its target price for Emcure Pharma to ₹1,625, implying a potential upside of nearly 40% from current levels. The brokerage cited strong growth visibility, margin resilience, and sustained demand trends as key drivers behind its bullish stance.
At the end of Thursday’s session, the company’s market capitalization stood at ₹24,490 crore, with a P/E ratio of 40.41. The stock has now entered a strong upward trajectory and remains on investor watchlists.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
